HOME >> BIOLOGY >> NEWS
Nanotechnology requires immediate changes in EPA

WASHINGTON Regulatory oversight of nanotechnology is urgently needed and the Environmental Protection Agency (EPA) should act now, reports a new study released today. In EPA and Nanotechnology: Oversight for the 21st Century, former EPA assistant administrator for policy, planning and evaluation, J. Clarence (Terry) Davies, provides a roadmap for a new EPA to better handle the challenges of nanotechnology. New nanomaterials and nanotechnology products are entering the market each week, and an adequate oversight system is necessary to identify and minimize any adverse effects of nano materials and products on health or the environment. Davies' report sets out an agenda for creating an effective oversight system as nanotechnology advancesthe technology that some have hailed as "the next industrial revolution."

"This new report seeks to encourage EPA, Congress, and others to create an intelligent oversight approach that empowers EPA and promotes investment and innovation in new nanotechnology products and processes," said David Rejeski, director of the Project on Emerging Nanotechnologies at the Wilson Center (PEN). "As both the chair and ranking minority member of the U.S. House of Representatives Committee on Science and Technology stated last year, 'Nanotechnology is an area of research that could add billions of dollars to the U.S. economy, but that won't happen if it is shrouded in uncertainty about its [environmental, health and safety] consequences.' "

The report provides a thorough analysis of how nanotechnology can serve as a catalyst for change in EPA and existing regulatory frameworks. It identifies major areas that require transformation within the agencyincluding science, program integration, personnel, international activities and program evaluation. In addition, Davies' report spells out more than 25 steps that EPA, Congress, the president, the U.S. National Nanotechnology Initiative and the nanotechnology industry as a whole shoul
'"/>

Contact: Sharon McCarter
sharon.mccarter@wilsoncenter.org
202-691-4016
Project on Emerging Nanotechnologies
23-May-2007


Page: 1 2 3

Related biology news :

1. Nanotechnology helps scientists make bendy sensors for hydrogen vehicles
2. FDA Nanotechnology Task Force takes positive step forward
3. Nanotechnology, medicine and bioethics
4. Nanotechnology: consumers must be convinced benefits outweigh risks
5. Nanotechnology provides green path to environmentally sustainable economy
6. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
7. Green Nanotechnology: Its Easier Than You Think
8. Nanotechnologys past, present and future: A Congressional perspective
9. Nanotechnology oversight requires thinking outside the box
10. Change in webcast time for Wednesday event on NIOSH Nanotechnology Research Center progress report
11. Nanotechnology meets biology and DNA finds its groove

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nanotechnology requires immediate changes EPA

(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: